SELLAS Life Sciences Group Inc. (SLS), a late-stage clinical biopharmaceutical company, has key milestones ahead in the coming weeks.The company's lead product candidate is Galinpepimut-S (GPS), licensed from Memorial Sloan Kettering Cancer Center, and it targets the WT1 protein, which is present in an array of tumor types.A phase III study of GPS in acute myeloid leukemia patients who have achiev...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.